Form 4: Larimar Therapeutics CFO Michael Celano Reports Acquisition of Stock Options and Restricted Stock Units
SEC Form 4 Filing
Michael Celano, CFO of Larimar Therapeutics, reports the acquisition of stock options and restricted stock units.
Summary
- On January 22, 2025, Michael Celano, the Chief Financial Officer of Larimar Therapeutics, acquired 34,185 shares of common stock represented by restricted stock units (RSUs) at a price of $0.00.
- Each RSU represents a contingent right to receive one share of Larimar Therapeutics' Common Stock upon settlement.
- Celano also acquired 205,111 stock options with an exercise price of $3.46, exercisable beginning January 22, 2026, and expiring on January 22, 2035.
- Following these transactions, Celano directly owns 178,181 shares of common stock and 205,111 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment. This is a standard SEC filing reflecting compensation and doesn't inherently indicate positive or negative news.
Positives
- The acquisition of stock options and RSUs by the CFO signals confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedule of the stock options suggests a multi-year commitment from the CFO.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and alignment with shareholder interests.
Stakeholder Impact
- The acquisition of stock options and RSUs aligns the CFO's interests with those of the shareholders, potentially incentivizing value creation.
Key Dates
| Date | Description |
|---|---|
| 01/22/2025 | Date of transaction: Acquisition of RSUs and stock options. |
| 01/22/2026 | First vesting date for 25% of the acquired stock options. |
| 01/22/2035 | Expiration date of the acquired stock options. |
| 01/24/2025 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.